HAVCR2 and neoplasm: Combination therapy targeting TIM-3 and PD-1 mAb has already been tested in several solid tumor, and an ongoing Phase 1 clinical trial is currently evaluating the dosage and anti-tumor efficacy of a humanized anti-TIM-3 antibody in advanced solid tumors (NCT02817633) (54).